# Why biotech cycles can open timely growth opportunities

- Link: https://www.directorstalkinterviews.com/why-biotech-cycles-can-open-timely-growth-opportunities/4121255373
- Published: 2026-07-03T11:42:00+01:00
- Author: Amilia Stone

Biotech cycles can create attractive opportunities when share prices move ahead 
of the underlying science, especially during weaker market periods. In downturns,
smaller drug developers often face tighter funding conditions, high cash burn, and
slower regulatory timelines. These pressures can weigh heavily on valuations, even
when clinical progress remains intact. In some cases, companies can trade below 
the value of the cash they hold, creating a clear gap between market pricing and
potential asset value.

That gap is important because scientific progress can continue while market sentiment
remains weak. Trials can move forward, data can mature, and a therapy can become
more de-risked even before the share price reflects that progress. This is one of
the reasons biotech cycles can be compelling. The market may focus on near-term 
funding pressure, while the company continues to build value through clinical development.

A major turning point is often human proof of concept. Phase II clinical data can
show whether a therapy works in patients, which is a significant step beyond early
safety testing or preclinical research. When a company reaches this stage successfully,
its value can be reassessed quickly because the asset is no longer viewed only as
a scientific idea. It becomes a more credible clinical opportunity with clearer 
development potential.

Companies that manage downturns well can therefore emerge in a stronger position.
Those with enough cash, disciplined spending, focused programmes, and meaningful
upcoming data may be better placed to benefit when sentiment improves. A difficult
market can also help separate stronger platforms from weaker ones, directing attention
towards companies with the science, management focus, and development strategy needed
to progress.

Large pharmaceutical companies add further support to this cycle. Many major drugmakers
face patent cliffs as established medicines lose exclusivity and future revenue 
streams become less secure. This creates ongoing demand for new assets that can 
refresh pipelines and support future growth. Clinical-stage biotech companies with
de-risked therapies can become highly relevant in this environment, particularly
when valuations are still low compared with the potential value of their programmes.

_**Biotech Growth Trust plc** (LON:BIOG) seeks capital appreciation through investment
in the worldwide biotechnology industry. The Company and the Company’s Portfolio
Manager believe that there is a high congruence between companies that seek to act
responsibly and those that succeed in building long-term shareholder value. _

Share on:
